| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1371695 | Bioorganic & Medicinal Chemistry Letters | 2012 | 4 Pages |
Abstract
The 70-kDa ribosomal protein S6 kinase (p70S6K) is part of the PI3K/AKT/mTOR pathway and has been implicated in cancer. High throughput screening versus p70S6K led to the identification of aminopyrimidine 3a as active inhibitor. Lead optimization of 3a resulted in highly potent, selective, and orally bioavailable pyrazolopyrimidines. In this manuscript we report the structure–activity relationship of this series and pharmacokinetic, pharmacodynamic, and efficacy data of the lead compound 13c.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Joerg Bussenius, Neel K. Anand, Charles M. Blazey, Owen J. Bowles, Lynne Canne Bannen, Diva S.-M. Chan, Baili Chen, Erick W. Co, Simona Costanzo, Steven C. DeFina, Larisa Dubenko, Stefan Engst, Maurizio Franzini, Ping Huang, Vasu Jammalamadaka,